CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts
CytoReason has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to enhance its disease models and proprietary data, enabling faster and more precise decision-making for R&D leaders in partner companies. The investment will allow CytoReason to expand its model applications, increase its molecular and clinical data, and establish an office in Cambridge, Massachusetts. This funding comes as the company has recently strengthened its partnerships with major pharmaceutical firms, including Pfizer, and now serves six of the world’s top ten pharma companies. CytoReason's technology aids in improving R&D timelines and the probability of technical and regulatory success. With a focus on leveraging AI and computational disease models, CytoReason aims to revolutionize data usage in pharma R&D, ultimately benefiting patient care worldwide.